Authorized purpose: Concurrent detection and characterization support for screening DBT mammography
Clinical role
Concurrent detection, localization and diagnostic support
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Adjunct concurrent interpretation only; physician review remains required. Siemens compatibility and prior-exam processing have distinct validation cohorts and must not be assumed interchangeable across acquisition systems.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Concurrent detection and characterization support for screening DBT mammography
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: DICOM DBT image stacks and associated FFDM and/or synthetic 2D images from compatible Hologic, GE and Siemens systems; prior-exam processing evaluated for Hologic and GE
Who uses it?Intended users: Interpreting physicians qualified to read screening mammography
What does the software produce?Output: Finding bounding boxes, Finding Suspicion Level and Case Suspicion Level; DICOM Structured Report for markings and DICOM Secondary Capture summary report
What is its most important limitation?Key limitation: Adjunct concurrent interpretation only; physician review remains required. Siemens compatibility and prior-exam processing have distinct validation cohorts and must not be assumed interchangeable across acquisition systems.
Clinical takeaway. Clinical role: Concurrent detection and characterization support for screening DBT mammography
Evidence takeaway. Evidence from the reviewed source record: Two retrospective blinded standalone studies: 2,425 DBT cases (509 Siemens, 514 GE, 1,402 Hologic) and 684 current/prior patients from Hologic and GE. The summary reports successful noninferiority endpoints without usable sensitivity/specificity point estimates.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Concurrent detection and characterization support for screening DBT mammography
DICOM DBT image stacks and associated FFDM and/or synthetic 2D images from compatible Hologic, GE and Siemens systems; prior-exam processing evaluated for Hologic and GE
Adjunct concurrent interpretation only; physician review remains required. Siemens compatibility and prior-exam processing have distinct validation cohorts and must not be assumed interchangeable across acquisition systems.
Two retrospective blinded standalone studies: 2,425 DBT cases (509 Siemens, 514 GE, 1,402 Hologic) and 684 current/prior patients from Hologic and GE. The summary reports successful noninferiority endpoints without usable sensitivity/specificity point estimates.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Two retrospective blinded standalone studies: 2,425 DBT cases (509 Siemens, 514 GE, 1,402 Hologic) and 684 current/prior patients from Hologic and GE. The summary reports successful noninferiority endpoints without usable sensitivity/specificity point estimates.
Submission summary describes noninferiority but does not report a usable exact-version sensitivity estimate with operating point.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-05
Exact-version specificity point estimate and operating point were not established in the reviewed summary.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM DBT image stacks and associated FFDM and/or synthetic 2D images from compatible Hologic, GE and Siemens systems; prior-exam processing evaluated for Hologic and GE
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Finding bounding boxes, Finding Suspicion Level and Case Suspicion Level; DICOM Structured Report for markings and DICOM Secondary Capture summary report
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DeepHealth identifies SmartMammo Dx as also known as Saige DX within the multi-component SmartMammo offering
product family · checked 2026-09-06
The 2024 announcement predates K253825; other SmartMammo components and later rebranded products are not automatically capabilities of this submission.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-06Last searched
19Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored PubMed candidate reviewed and retained as contextual family economic modeling; no exact-version outcomes or payer coverage promoted. Stored clinical-trial candidate array is empty. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, literature index, peer reviewed publication, trial registry, recall database, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission
A published family economic model references a consumer screening add-on charge. This does not establish K253825 procurement cost, a current quote or a software-only price.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "DeepHealth Saige-Dx reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Deployment: Not verified - checked 2026-09-05 - Exact FDA submission
Exact hosting topology, hardware requirements and contracted PACS integration were not established.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-05 - Exact FDA submission
No scoped dated attestation for the Saige-Dx deployment was reviewed.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact FDA submission
Site training, suspicion-score interpretation curriculum and competency assessment remain unestablished.
Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission
Post-deployment false-positive/false-negative auditing and update-specific acceptance requirements remain to be confirmed.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
Authorized purpose: Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.